The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a " Medication Event Monitoring System " (MEMS®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.

Inclusion Criteria:

• Age > 18 years
• histologically proven malignant tumor
• documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor
• ambulatory treated subject
• Subject who accept to use MEMS monitors to automatically compile their drug dosing histories
• Written informed consent

Exclusion Criteria:

• any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol
• patient who does not agreed to participate the program